MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: A clinico-laboratory assessment
<p>Introduction</p><p>This database includes the raw data linked with the paper "MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: A clinico-laboratory assessment " to be published on "Journal of Neurology Neurosurgery and Psychiatry". </p><p>In this paper, we reported clinical, radiological and laboratory data concerning thirty-eight individuals diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) to assess the impact of the criteria-based MOG-IgG testing in MOGAD diagnosis. </p><p>Methods</p><p>Thirty-eight serum samples of MOG-IgG1-positive MOGAD patients were titred on MOG-IgG LCBA and FCBA, and the presence of supporting features for MOGAD assessed. MOGAD criteria were evaluated in three testing scenarios: a) FCBA without titration; b) FCBA with titration; c) LCBA with titration.</p><p>Results (in brief)</p><p>FCBA without titration failed to reach MOGAD diagnosis in 11/38 patients (28.9%, negative results in 5, lack of supporting features in 6). Patients with unconfirmed diagnosis had optic neuritis (ON, n=8), or transverse myelitis (TM, n=3). FCBA with titration allowed MOGAD diagnosis in 4 additional patients. Correlation between LCBA and FCBA titres was moderate (Spearman's rho 0.6, p<0.001).</p>
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 4
- Access
- 8
- Reuse readiness
- 0
- Engagement
- 0
Topics
Dataset details
- Repository
- zenodo
- Published
- November 1, 2023
- License
- cc-by-4.0
- DOI
- 10.5281/zenodo.10067021
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.